P96.2 Withdrawal symptoms from therapeutic use of drugs in newborn

Name of the Condition

• Withdrawal symptoms from therapeutic use of drugs in newborn
• ICD-10 Code: P96.2

Summary

This code describes withdrawal symptoms in newborns resulting from the therapeutic use of drugs by the mother during pregnancy. These symptoms occur due to the infant's exposure to medications that cross the placenta, leading to physiological dependence and subsequent withdrawal after birth. The condition requires clinical assessment to determine the extent of symptoms and guide management.

Causes

The condition arises when a pregnant individual uses therapeutic drugs (e.g., opioids, benzodiazepines, antidepressants) that pass to the fetus, causing dependence. After birth, the abrupt cessation of drug exposure triggers withdrawal as the infant's body adjusts to the absence of the substance. The specific drugs involved and their duration of use influence the severity of symptoms.

Risk Factors

• Prolonged maternal use of therapeutic drugs during pregnancy.
• Use of drugs with known withdrawal potential (e.g., opioids, sedatives).
• Higher doses or frequent administration of the drug.
• Abrupt discontinuation of maternal medication near delivery.

Symptoms

• Irritability, excessive crying, or tremors.
• Feeding difficulties, poor suckling, or vomiting.
• Hypertonia (increased muscle tone) or hypertonicity.
• Seizures, jitteriness, or abnormal movements.
• Respiratory distress, tachypnea, or apnea.
• Gastrointestinal issues like diarrhea or poor weight gain.

Diagnosis

Diagnosis is based on clinical evaluation, including a detailed maternal medication history and observation of newborn symptoms. Laboratory tests (e.g., drug screening) may confirm exposure, but symptoms alone often guide diagnosis. The timing of symptom onset (typically within 72 hours of birth) and correlation with maternal drug use are critical.

Treatment Options

• Supportive care to manage symptoms (e.g., swaddling, quiet environment).
• Pharmacological interventions (e.g., tapering doses of the causative drug or using alternative medications to ease withdrawal).
• Monitoring for respiratory distress or seizures.
• Nutritional support to address feeding difficulties.

Prognosis and Follow-Up

Prognosis depends on the severity of symptoms and timely intervention. Most infants recover with appropriate management, but some may experience prolonged withdrawal or developmental delays. Follow-up includes monitoring growth, neurodevelopment, and addressing any long-term effects of the maternal drug use.

Complications

• Severe withdrawal leading to respiratory failure or seizures.
• Dehydration or failure to thrive from feeding difficulties.
• Neurodevelopmental delays if symptoms are prolonged or untreated.
• Increased risk of future substance use disorders (controversial, requires further study).

Lifestyle & Prevention

• Maternal counseling on the risks of therapeutic drug use during pregnancy.
• Gradual tapering of medications under medical supervision before delivery when possible.
• Postnatal monitoring for early symptom detection.
• Support for breastfeeding, as it may aid in withdrawal management.

When to Seek Professional Help

Seek immediate medical attention if the newborn exhibits severe symptoms (e.g., seizures, respiratory distress) or fails to feed. Persistent irritability, poor weight gain, or unexplained crying beyond the typical withdrawal window also warrant evaluation.

Tips for Medical Coders

Document the maternal drug history, including the specific therapeutic agent, duration of use, and timing relative to delivery. Note the onset and severity of newborn symptoms, as well as any interventions. Ensure the code is applied only when withdrawal is attributed to therapeutic (not illicit) drug use, and avoid coding if symptoms are due to other causes.